治疗转移性结直肠癌的Ziv-阿柏西普的临床研究进展; Progression of Ziv-aflibercept on metastatic colorectal cancer | |
宋敏 | |
2015-09-25 | |
关键词 | Ziv-阿柏西普 结直肠肿瘤 受体 血管内皮生长因子 Ziv-aflibercept colorectal neoplasms receptors vascular endothelial growth factor |
英文摘要 | 针对特异性分子靶点的靶向药物治疗已成为转移性结直肠癌(M CrC)治疗的新方向。2012年zIV-阿柏西普被美国食品和药物管理局批准用于M CrC患者,zIV-阿柏西普是一种作用于血管生成信号通路的重组融合蛋白,通过与血管内皮生长因子(VEgf)受体结合,从而阻断肿瘤的生长和转移。一项Ⅲ期临床研究结果显示zIV-阿柏西普能显著延长M CrC患者的生存期。本文结合国内外最新研究报道,对zIV-阿柏西普治疗M CrC的研究进展作一综述。; Targeted drug therapy for specific molecular targets has become a new direction of treatment for metastatic colorectal cancer(m CRC).Ziv-Aflibercept was approved by the U.S.Food and Drug Administration for use in the patients with m CRC in 2012.Ziv-Aflibercept is a novel recombinant fusion protein which can inhibit growth and metastasis of tumor by blocking vascular endothelial growth factor( VEGF) receptors.A phase Ⅲ clinical trial showed the benefit of Ziv-aflibercept on the overall survival of m CRC patients.In this paper, the progression of Ziv-aflibercept on m CRC are summarized. |
语种 | zh_CN |
内容类型 | 期刊论文 |
源URL | [http://dspace.xmu.edu.cn/handle/2288/123619] |
专题 | 药学院-已发表论文 |
推荐引用方式 GB/T 7714 | 宋敏. 治疗转移性结直肠癌的Ziv-阿柏西普的临床研究进展, Progression of Ziv-aflibercept on metastatic colorectal cancer[J],2015. |
APA | 宋敏.(2015).治疗转移性结直肠癌的Ziv-阿柏西普的临床研究进展.. |
MLA | 宋敏."治疗转移性结直肠癌的Ziv-阿柏西普的临床研究进展".(2015). |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论